Resources

Customer stories from teams like yours, how Sleuth compares with the tools you use now, and Sleuth’s news and perspectives.

Customer stories

Kind of team

How they used Sleuth

No customer stories match these filters

Benchmarks

No items found.
Explore benchmarks

All resources

Customer Stories

How Pencil chose its first program before its raise

Sleuth provides a confidence score for every value, so you know which to trust and which to review. Pencil Biosciences, a seed-stage gene-editing company, could potentially aim its platform at many diseases. With a raise coming up, it needed to select one lead program it could defend to investors.

November 13, 2026
Biotech
Concierge
Pencil Bio
Customer Stories

How Juvena’s CSO keeps up with a first-in-class pipeline

Sleuth Studio lets one person do deep analysis and triage across a first-in-class pipeline. Juvena Therapeutics’ discovery work turns up targets across hundreds of indications, and co-founder and CSO Jeremy O’Connell researches each new target in Studio: the biology behind it, who else is drugging it, and how fast a trial could show it works.

November 13, 2026
Biotech
Sleuth Studio
Juvena Therapeutics
Customer Stories

A custom dataset, built to spec and updated weekly

Sleuth builds a dataset to your spec, checks it, and delivers it weekly. This one helps a health-tech company show hospitals what they need to prepare for new, advanced therapies.

November 13, 2026
Diagnostics and Health Tech
Custom Datasets
A health-tech company
Customer Stories

How one of the largest diagnostics companies reaches drug developers before they pick a partner

Sleuth shows companies that sell to pharma which drug developers to reach, and when, from a live view of the market. One of the world’s largest oncology diagnostics companies used Studio to map every program in four newer kinds of cancer drug, see which patients the late-stage trials will add, and find the sponsors whose partner decisions are coming up.

November 13, 2026
Diagnostics and Health Tech
Sleuth Studio
A global oncology diagnostics company
Customer Stories

How a top-10 pharma runs research across five teams in Studio

Sleuth is market intelligence infrastructure for whole pharma teams. At one top-10 pharma, five teams, from business development to R&D, bring their hardest questions to Studio and get back answers that were previously buried in the data.

November 13, 2026
Pharma
Sleuth Studio
A global top-10 pharma
Customer Stories

How past liver-safety failures helped DART-Met weigh where to start

Sleuth shows founders what has failed in their field and why, so they can choose where to start. Suraj Pavagada was developing a new way to detect liver injury as a Stanford researcher, with no commercial team and investor meetings weeks away. Sleuth’s analysts reviewed ten years of liver-safety setbacks and surfaced a promising opportunity in about a week.

November 13, 2026
Biotech
Concierge
DART-Met
Industry Perspectives

Choosing a Lead Indication (Biotech Strategy Series)

Biotechs rarely have too few indication options. In this post, we walk through a funnel for making defensible cuts, from hundreds of candidates to one lead indication.

September 22, 2026
Industry Perspectives

Creating Competitive Landscapes for Fundraise Decks (Biotech Strategy Series)

The competitive landscape should drive every decision an early biotech makes. In this post, we walk through how to build a fundraise-ready competitive landscape.

August 25, 2026
Industry Perspectives

What Compounding Intelligence Looks Like

Compounding intelligence is not just using AI to make outputs - it's building a system in which every piece of work improves the next decision.

August 24, 2026
Industry Perspectives

Biopharma Data in an Age of AI

AI has removed the constraints that forced every team to interrogate the world through the same datasets.

August 17, 2026
Customer Stories

How LionBio found the real bar for its GLP-1

Sleuth shows you the bar your program has to clear, in trials and everyday care. LionBio was developing a GLP-1 nasal spray, and CEO Robin Guo expected it to cause less nausea than weekly injections. Sleuth’s analysts compared how long patients stay on GLP-1s, in trials and in everyday care. The bar turned out to be keeping patients on the drug.

August 13, 2026
Biotech
Concierge
LionBio
Industry Perspectives

Where Top Pharma Is Focusing Its AI Efforts

One insight stands out in how top-25 Pharma companies are bringing AI into their organizations: intentionality.

August 11, 2026
Industry Perspectives

The Last Mile from Output to Decision

AI is collapsing the cost of producing biopharma intelligence. The bottleneck has shifted from building the output to verifying it, defending it, and acting on it.

August 10, 2026
In the News

WSJ: U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

Sleuth data featured in The Wall Street Journal

July 9, 2026
Technical Perspectives

Why our AI Asks Fewer Questions (and Gets Better Answers)

What a 12,000-indication landscape taught us about building multi-agent biopharma analysis systems

May 19, 2026
Industry Perspectives

What Powers Sleuth

A look under the hood at the infrastructure powering Sleuth: a continuously maintained knowledge graph of the biopharma landscape, structured through extraction and validation, designed to produce traceable, decision-grade analysis.

April 24, 2026
Customer Stories

How a nine-person biotech chose its lead indications in Studio

Sleuth Studio lets small teams screen indications on their own criteria and refine the analysis as questions change. Epana Bio used it to decide which indications to pursue first, one of the highest-stakes calls an early biotech makes.

April 23, 2026
Biotech
Sleuth Studio
Epana Bio
Customer Stories

How Daiichi Sankyo built a peer database for its strategy questions

Sleuth Concierge delivers consulting-grade work in a fraction of the time and cost, and the work doesn’t go stale after the handoff. At Daiichi Sankyo, each new strategy question builds on the same peer database.

April 22, 2026
Pharma
Concierge
Daiichi Sankyo
Announcements

Sleuth Launches from Stealth with $8M to Modernize Biopharma Decision-Making

Sleuth Insights launched from stealth with $8M in seed funding led by Bison Ventures to modernize how biopharma strategy, BD and competitive intelligence teams make decisions.

April 21, 2026
Announcements

Andrew Pannu on Launching Sleuth

Sleuth's founder and CEO on what the team built, why it matters now, and what it means for biopharma intelligence teams.

April 21, 2026
Announcements

Sleuth Studio Trailer

Biopharma analyses tailored to your questions, grounded in connected evidence, ready for executive conversations. Sleuth Studio in 90 seconds.

April 21, 2026
Industry Perspectives

Closing the Biopharma Intelligence Gap

Today we're opening up the intelligence infrastructure we've spent two years running underneath pharma and biotech engagements. A look at how Sleuth Studio works, why connected data changes what AI can do, and what it means for high-stakes decisions.

April 21, 2026
Industry Perspectives

The Biopharma Intelligence Gap

Most biopharma intelligence teams are running two races at once: the sprint to get smart fast, and the marathon of keeping the competitive picture current. In theory they should compound. In practice they never do. A look at why, and what needs to change.

April 14, 2026

No resources match

Run Sleuth on your own question

Set up in Claude, ChatGPT, or Copilot